Punto di vista degli analisti
La somministrazione transmucosale di farmaci coinvolge le membrane mucose come mucosa orale, mucosa nasale, mucosa rettale, mucosa vaginale, mucosa oculare mucosa e mucosa polmonare per la somministrazione dei farmaci. Maggiore biodisponibilità, rapida insorgenza d’azione, elusione del metabolismo di primo passaggio e facilità di somministrazione sono i principali vantaggi di questo sistema di somministrazione dei farmaci rispetto alle tradizionali vie di somministrazione dei farmaci. Il rapporto include prospettive di crescita dovute alle attuali tendenze del mercato dei sistemi di somministrazione di farmaci per via transmucosa e al loro impatto prevedibile durante il periodo di previsione.
Fattori che guidano la crescita del mercato dei sistemi di somministrazione di farmaci per via transmucosa via di somministrazione del farmaco a causa dell’efficacia prolungata di questo tipo di somministrazione. Le vie transmucose come intranasale, buccale, sublinguale e rettale sono metodi non invasivi per la somministrazione sistemica di farmaci. Sono particolarmente utili poiché gli operatori sanitari o i pazienti possono somministrare questi farmaci senza la necessità di personale esperto. Inoltre, una rapida insorgenza d’azione con un ridotto metabolismo di primo passaggio li rende ideali per le cure palliative e di fine vita. Funzionano velocemente per alleviare i sintomi e offrire ai pazienti un rapido sollievo. Di conseguenza, i sistemi di rilascio transmucoso sono diventati una scelta popolare nella gestione di varie malattie croniche, come malattie cardiovascolari, diabete e malattie respiratorie croniche. Secondo un articolo pubblicato da PubMed Central nel gennaio 2020, è stato condotto uno studio per l'indagine e il confronto della sicurezza e della farmacocinetica della diidroergotamina (DHE) quando somministrata sotto forma di polvere intranasale di DHE (STS101), spray intranasale di DHE (Migranal ) e iniezione intramuscolare (IM) di DHE in soggetti sani. Lo studio ha concluso che STS101 è un trattamento acuto per l'emicrania, facile da somministrare, non iniettabile, con un profilo di tollerabilità favorevole. Si prevede inoltre che faciliti un sollievo rapido e consistente dal dolore e sopprima i sintomi dell'emicrania senza recidive.
Numerosi farmaci farmacologici sono offerti come formazioni transmucose orali; questi includono agenti cardiovascolari, sedativi e analgesici. Le pellicole orali biodegradabili aiutano nella somministrazione dei farmaci alla circolazione sistemica, il che è molto vantaggioso per le persone con disfagia, vomito ripetuto, ipertensione, infarto, asma, nausea, paralisi e disturbi mentali. Queste pellicole orali a rapida dissoluzione sono sottili strisce adesive che vengono posizionate sulla lingua del paziente o su qualsiasi tessuto della mucosa orale.
Pertanto, vantaggi quali facilità di somministrazione, elevata biodisponibilità, disponibilità sistemica del farmaco e azione rapida alimentano il Crescita del mercato dei sistemi di somministrazione di farmaci transmucosi.
Approfondimenti strategici
Segmentazione e ambito del rapporto
L'analisi del mercato globale dei sistemi di somministrazione di farmaci transmucosi fino al 2031 è un'analisi specializzata e approfondita studio dell'industria farmaceutica con particolare attenzione all'analisi delle tendenze del mercato globale. L’obiettivo del rapporto è fornire una panoramica del mercato con una segmentazione dettagliata del mercato basata su sistemi, utente finale e area geografica. Fornisce statistiche chiave sui principali attori del mercato e menziona le principali tendenze e opportunità prevalenti nel mercato. L’ambito del rapporto sul mercato globale dei sistemi di somministrazione di farmaci transmucosi comprende Nord America (Stati Uniti, Canada e Messico), Europa (Germania, Francia, Italia, Regno Unito, Spagna e resto d’Europa), Asia Pacifico (Cina, Giappone, India, Australia, Corea del Sud e resto dell'Asia Pacifico), Medio Oriente e Africa (Sudafrica, Arabia Saudita, Emirati Arabi Uniti e resto del Medio Oriente e Africa) e America meridionale e centrale (Brasile, Argentina e resto del Sud e America Centrale).
Approfondimenti basati sui sistemi
Sulla base dei sistemi, il mercato è segmentato in nasopolmonare, buccale e sublinguale, vaginale e altri. Il segmento nasopolmonare ha detenuto la maggiore quota di mercato dei sistemi di somministrazione di farmaci transmucosi nel 2023 e si prevede che registrerà il CAGR più elevato dal 2023 al 2031.
Approfondimenti basati sull'utente finale
In base all'utente finale, il il mercato è segmentato in strutture sanitarie, strutture di assistenza domiciliare e altri. Il segmento delle strutture sanitarie ha detenuto la quota di mercato maggiore nel 2023. Ciò può essere attribuito alla disponibilità di strutture migliori e di medici qualificati negli ospedali. Inoltre, si prevede che il segmento delle strutture di assistenza domiciliare manterrà il CAGR più elevato dal 2023 al 2031.
Mercato dei sistemi di somministrazione di farmaci transmucosi, per utente finale: 2023 e 2031
Analisi regionale
In base alla geografia, il mercato è segmentato principalmente in Nord America, Asia Pacifico, Europa, Medio Oriente e Africa e America meridionale e centrale. In termini di entrate, nel 2023 il Nord America deteneva la maggiore quota di mercato dei sistemi di somministrazione di farmaci transmucosi. Gli Stati Uniti dominano il mercato in questa regione. Ciò può essere attribuito all'aumento dei casi di malattie croniche come diabete, asma e malattie cardiache, nonché al crescente numero di lanci di prodotti da parte di attori chiave.
Sviluppi del settore e opportunità future:
Le previsioni di mercato dei sistemi di somministrazione di farmaci transmucosi possono aiutare le parti interessate in questo mercato a pianificare le proprie strategie di crescita. Secondo i comunicati stampa dell'azienda, sono elencati di seguito alcuni sviluppi strategici dei principali attori che operano nel mercato globale:
•Nel febbraio 2024, Aquestive Therapeutics, Inc. ha presentato un poster all'American Academy of Allergy, Asthma, and Immunology (AAAAI) 2024 meeting annuale a Washington, DC, che mette in evidenza i dati positivi di farmacocinetica (PK) e farmacodinamica (PD) di due studi clinici completi su pellicola sublinguale di Anaphylm (epinefrina). Nell'agosto 2022, iX Biopharma Ltd ha lanciato IXB-322, un nuovo programma per espandere la sua pipeline. Il programma mira a sviluppare un wafer sublinguale di dexmedetomidina per il trattamento dell'agitazione nella demenza e in altre indicazioni. Questa iniziativa fa parte della strategia di iX Biopharma volta a riutilizzare i farmaci approvati esistenti utilizzando la tecnologia proprietaria della piattaforma di somministrazione dei farmaci WaferiX.•Nel maggio 2021, Tillotts Pharma AG, una parte del gruppo giapponese Zeria, ha aggiunto un nuovo farmaco al suo portafoglio di gastroenterologia con il lancio di AsacolTM 1g (mesalazina). La supposta ad alto dosaggio è usata per trattare i sintomi della proctite ulcerosa da lieve a moderata negli adulti. Questo lancio aiuterà l’azienda a offrire terapie innovative ai pazienti con malattie gastrointestinali. Le supposte AsacolTM 1g forniscono una comoda forma di trattamento per le persone che soffrono di proctite ulcerosa, poiché richiedono solo una singola dose giornaliera.•Nell'aprile 2021, Teva Pharmaceuticals USA, Inc., una filiale statunitense di Teva Pharmaceutical Industries Ltd., ha annunciato il rilascio della sua versione generica del medicinale in supposta Casana 1 (mesalamina). Il medicinale è indicato per il trattamento della proctite ulcerosa attiva (colite rettale ulcerosa) negli Stati Uniti.Teva Pharmaceutical Industries Ltd; Cigna Corporation.; BioDelivery Sciences International, Inc; 3M; Henkel Finlandia Oy; GlaxoSmithKline plc; Aquestive Therapeutics, Inc; Camurus AB; Ximedica; e Noven Pharmaceuticals, Inc. sono alcune delle principali aziende descritte nel rapporto sul mercato dei sistemi di somministrazione di farmaci transmucosi. Questi attori leader si concentrano sull’espansione e sulla diversificazione della propria presenza sul mercato e della propria clientela, sfruttando le opportunità di business nel mercato.
Report Coverage
Revenue forecast, Company Analysis, Industry landscape, Growth factors, and Trends
Segment Covered
This text is related
to segments covered.
Regional Scope
North America, Europe, Asia Pacific, Middle East & Africa, South & Central America
Country Scope
This text is related
to country scope.
Frequently Asked Questions
The transmucosal drug delivery involves mucosal membranes such as oral mucosa, nasal mucosa, rectal mucosa, vaginal mucosa, ocular mucosa, and pulmonary mucosa for drug administration. Higher bioavailability, rapid onset of action, evasion of first-pass metabolism, and ease of administration are the key advantages of this drug delivery system over traditional routes of drug administration.
Key factors driving the transmucosal drug delivery systems market growth is rising adoption of drug delivery systems for disease management and the development of new drug molecules and biological formulations.
The transmucosal drug delivery systems market was valued at US$ 80.21 billion in 2023.
The transmucosal drug delivery systems market majorly consists of the players, including Teva Pharmaceutical Industries Ltd; Cigna Corporation.; BioDelivery Sciences International, Inc; 3M; Henkel Finland Oy; GlaxoSmithKline plc; Aquestive Therapeutics, Inc; Camurus AB; Ximedica; and Noven Pharmaceuticals, Inc.
The transmucosal drug delivery systems market is expected to be valued at US$ 129.46 billion in 2031.
The transmucosal drug delivery systems market, by systems, is bifurcated into nasopulmonary, buccal & sublingual, vaginal, and others. The nasopulmonary segment held a larger market share in 2023.
The List of Companies - Transmucosal Drug Delivery Systems Market
- Teva Pharmaceutical Industries Ltd
- Cigna Corporation
- BioDelivery Sciences International, Inc
- 3M
- Henkel Finland Oy
- GlaxoSmithKline plc
- Aquestive Therapeutics, Inc
- Camurus AB
- Ximedica
- Noven Pharmaceuticals, Inc
The Insight Partners performs research in 4 major stages: Data Collection & Secondary Research, Primary Research, Data Analysis and Data Triangulation & Final Review.
- Data Collection and Secondary Research:
As a market research and consulting firm operating from a decade, we have published and advised several client across the globe. First step for any study will start with an assessment of currently available data and insights from existing reports. Further, historical and current market information is collected from Investor Presentations, Annual Reports, SEC Filings, etc., and other information related to company’s performance and market positioning are gathered from Paid Databases (Factiva, Hoovers, and Reuters) and various other publications available in public domain.
Several associations trade associates, technical forums, institutes, societies and organization are accessed to gain technical as well as market related insights through their publications such as research papers, blogs and press releases related to the studies are referred to get cues about the market. Further, white papers, journals, magazines, and other news articles published in last 3 years are scrutinized and analyzed to understand the current market trends.
- Primary Research:
The primarily interview analysis comprise of data obtained from industry participants interview and answers to survey questions gathered by in-house primary team.
For primary research, interviews are conducted with industry experts/CEOs/Marketing Managers/VPs/Subject Matter Experts from both demand and supply side to get a 360-degree view of the market. The primary team conducts several interviews based on the complexity of the markets to understand the various market trends and dynamics which makes research more credible and precise.
A typical research interview fulfils the following functions:
- Provides first-hand information on the market size, market trends, growth trends, competitive landscape, and outlook
- Validates and strengthens in-house secondary research findings
- Develops the analysis team’s expertise and market understanding
Primary research involves email interactions and telephone interviews for each market, category, segment, and sub-segment across geographies. The participants who typically take part in such a process include, but are not limited to:
- Industry participants: VPs, business development managers, market intelligence managers and national sales managers
- Outside experts: Valuation experts, research analysts and key opinion leaders specializing in the electronics and semiconductor industry.
Below is the breakup of our primary respondents by company, designation, and region:
Once we receive the confirmation from primary research sources or primary respondents, we finalize the base year market estimation and forecast the data as per the macroeconomic and microeconomic factors assessed during data collection.
- Data Analysis:
Once data is validated through both secondary as well as primary respondents, we finalize the market estimations by hypothesis formulation and factor analysis at regional and country level.
- Macro-Economic Factor Analysis:
We analyse macroeconomic indicators such the gross domestic product (GDP), increase in the demand for goods and services across industries, technological advancement, regional economic growth, governmental policies, the influence of COVID-19, PEST analysis, and other aspects. This analysis aids in setting benchmarks for various nations/regions and approximating market splits. Additionally, the general trend of the aforementioned components aid in determining the market's development possibilities.
- Country Level Data:
Various factors that are especially aligned to the country are taken into account to determine the market size for a certain area and country, including the presence of vendors, such as headquarters and offices, the country's GDP, demand patterns, and industry growth. To comprehend the market dynamics for the nation, a number of growth variables, inhibitors, application areas, and current market trends are researched. The aforementioned elements aid in determining the country's overall market's growth potential.
- Company Profile:
The “Table of Contents” is formulated by listing and analyzing more than 25 - 30 companies operating in the market ecosystem across geographies. However, we profile only 10 companies as a standard practice in our syndicate reports. These 10 companies comprise leading, emerging, and regional players. Nonetheless, our analysis is not restricted to the 10 listed companies, we also analyze other companies present in the market to develop a holistic view and understand the prevailing trends. The “Company Profiles” section in the report covers key facts, business description, products & services, financial information, SWOT analysis, and key developments. The financial information presented is extracted from the annual reports and official documents of the publicly listed companies. Upon collecting the information for the sections of respective companies, we verify them via various primary sources and then compile the data in respective company profiles. The company level information helps us in deriving the base number as well as in forecasting the market size.
- Developing Base Number:
Aggregation of sales statistics (2020-2022) and macro-economic factor, and other secondary and primary research insights are utilized to arrive at base number and related market shares for 2022. The data gaps are identified in this step and relevant market data is analyzed, collected from paid primary interviews or databases. On finalizing the base year market size, forecasts are developed on the basis of macro-economic, industry and market growth factors and company level analysis.
- Data Triangulation and Final Review:
The market findings and base year market size calculations are validated from supply as well as demand side. Demand side validations are based on macro-economic factor analysis and benchmarks for respective regions and countries. In case of supply side validations, revenues of major companies are estimated (in case not available) based on industry benchmark, approximate number of employees, product portfolio, and primary interviews revenues are gathered. Further revenue from target product/service segment is assessed to avoid overshooting of market statistics. In case of heavy deviations between supply and demand side values, all thes steps are repeated to achieve synchronization.
We follow an iterative model, wherein we share our research findings with Subject Matter Experts (SME’s) and Key Opinion Leaders (KOLs) until consensus view of the market is not formulated – this model negates any drastic deviation in the opinions of experts. Only validated and universally acceptable research findings are quoted in our reports.
We have important check points that we use to validate our research findings – which we call – data triangulation, where we validate the information, we generate from secondary sources with primary interviews and then we re-validate with our internal data bases and Subject matter experts. This comprehensive model enables us to deliver high quality, reliable data in shortest possible time.
Related Reports
Mar 2024
Aquatic Veterinary Market
Size and Forecast (2020 - 2030), Global and Regional Share, Trend, and Growth Opportunity Analysis Report Coverage: By Type (Diagnostics and Treatments), Species (Fish, Crustaceans, Mollusca, and Others), Disease Source (Bacteria, Viruses, Parasites, and Others), Route of Administration (Water Medication, Medicated Feed, and Others), and Geography (North America, Europe, Asia Pacific, Middle East & Africa, and South & Central America)
Mar 2024
Sickle Cell Disease Treatment Market
Size and Forecasts (2020 - 2030), Global and Regional Share, Trends, and Growth Opportunity Analysis By Treatment (Generic Drugs and Originators), Route of Administration (Oral and Parenteral), and Distribution Channel (Direct Tender, Hospital Pharmacies, Retail Pharmacies, Online Pharmacies, and Others)
Mar 2024
Malaria and Sickle Cell Disease Treatment Market
Size and Forecasts (2020 - 2030), Global and Regional Share, Trends, and Growth Opportunity Analysis Report Coverage: By Treatment [Malaria and Sickle Cell Disease (SCD)], Route of Administration (Oral and Parenteral), and Distribution Channel (Direct Tender, Hospital Pharmacies, Retail Pharmacies, Online Pharmacies, and Others)
Mar 2024
Pharmaceutical Contract Sales Organizations Market
Size and Forecasts (2020 - 2030), Global and Regional Share, Trends, and Growth Opportunity Analysis Report Coverage: By Services (Commercial Services and Non-Commercial Services), Modules (Syndicated Modules and Dedicated Modules), Therapeutic Area (Cardiovascular Disorders, Oncology, Metabolic Disorders, Neurology, Orthopedic Diseases, Infectious Diseases, and Others), End User (Biopharmaceutical Companies and Pharmaceutical Companies), and Geography (North America, Europe, Asia Pacific, Middle East & Africa, and South & Central America)
Mar 2024
Breast Cancer Therapeutics Market
Size and Forecasts (2020 - 2030), Global and Regional Share, Trends, and Growth Opportunity Analysis Report Coverage: By Drug Therapy [Targeted Drug Therapy (Abemaciclib, Ado-Trastuzumab Emtansine, Palbociclib, Trastuzumab, and Other Target Drug Therapies), Hormonal Drug Therapy (Selective Estrogen Receptor Modulators, Aromatase Inhibitors, and Selective Estrogen Receptor Downregulators), Chemotherapy, and Immunotherapy/Biological Therapy], Breast Cancer Type (Hormone Receptor, HER2+, and Triple-Negative Breast Cancer), Distribution Channel (Hospital Pharmacies, Drug Stores and Retail Pharmacies, and Online Pharmacies), and Geography (North America, Europe, Asia Pacific, Middle East & Africa, and South & Central America)
Mar 2024
Radioactive Tracer Market
Size and Forecast to 2030 - Global Analysis by Tracer Type [Technetium-99m & Tc-97m, Iodine-131, Iron-59, Lutetium-171, Rubidium (Rb-82) Chloride & Ammonia (N-13), Scandium-46, Seaborgium-269, Hassium-269, Gallium Citrate Ga 67, Prostate-Specific Membrane Antigen (PSMA) (Ga-68), FDDNP (F-18) & FDOPA (F-18), Phosphorus-32 & Chromium-51, Thallium-201, F-18 FDG, F-18 FAPI, Ga-68 FAPI, F-18 PSMA, DOTATOC/DOTANOC/DOTATATE (Ga-68), and Others], Test Type (PET, SPECT, and Others), Application (Oncology, Pulmonary, Neurology, Cardiology, and Others) End User (Hospitals & Clinics, Diagnostic Centers, Academic & Research Institutes, And Others), and Geography
Mar 2024
Glioma Treatment Market
Size and Forecasts (2020 - 2030), Global and Regional Share, Trends, and Growth Opportunity Analysis Report Coverage: By Disease (Astrocytoma, Oligoastrocytoma, and Oligodendroglioma), Treatment Type (Surgery, Chemotherapy, Radiation Therapy, and Others), Grade (Low Grade and High Grade), End User (Hospital & Clinics and Ambulatory Surgical Center), and Geography
Mar 2024
Hyperpigmentation Disorder Treatment Market
Size and Forecast (2020 - 2030), Global and Regional Share, Trend, and Growth Opportunity Analysis Report Coverage: By Treatment Type (Cosmeceutical, Light or Laser Therapy, Microdermabrasion, Chemical Peels, Cryotherapy, and Others), Condition (Melasma, Solar Lentigines, Post-Inflammatory Hyperpigmentation, and Others), End User (Hospitals, Dermatology Centers, and Others), and Geography (North America, Europe, Asia Pacific, South & Central America, and Middle East & Africa)